Trump Drug Summit Leaves Big Pharma Optimistic...maybe
Trump Drug Summit Leaves Big Pharma Optimistic...maybe
SUGAR LAND--February 9, 2017--Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas)--It was a wary group of Big Pharma heavyweights that made their way to Washington D.C. last week. Summoned by President Donald Trump, the industry and market collectively held their breath, uncertain of what lay ahead following the new president's recent recriminations against the industry. Instead of a visit to the woodshed, Big Pharma came away with cause to celebrate.
Within this article: Potential implications of meeting between President Donald Trump and leaders of big pharmaceutical companies.
Additional companies: Pfizer (NYSE:PFE), Merck & Co Inc. (NYSE:MRK), Amgen Inc. (NASDAQ:AMGN), Eli Lilly & Company (NYSE:LLY), Celgene Corp. (NASDAQ: CELG), Johnson & Johnson (NYSE:JNJ), Novartis AG (NYSE:NVS)
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects